IDP-118 Lotion

DRUG8 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Plaque PsoriasisPsoriasis

Phase 1

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT03058744

Bausch Health Americas, Inc.Psoriasis

Start: 2015-04-30End: 2017-01-31Updated: 2017-06-09

Phase 2

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

CompletedNCT02045277

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2014-02-28End: 2014-11-30Updated: 2020-08-20

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

CompletedNCT02785159

Bausch Health Americas, Inc.Psoriasis

Start: 2016-02-29End: 2016-12-31Updated: 2020-08-20

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

CompletedNCT02785172

Bausch Health Americas, Inc.Psoriasis

Start: 2016-04-30End: 2017-01-31Updated: 2020-08-20

Phase 3

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

CompletedNCT02462083

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-08-11End: 2017-04-24Updated: 2020-01-27

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

CompletedNCT02462070

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-08-11End: 2016-12-01Updated: 2020-08-20

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

CompletedNCT02462122

Bausch Health Americas, Inc.Plaque Psoriasis

Start: 2015-08-19End: 2016-11-14Updated: 2020-08-20

Phase 4

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

RecruitingNCT03988439

Bausch Health Americas, Inc.Psoriasis

Start: 2021-03-24End: 2027-03-31Target: 45Updated: 2025-08-27

Related Papers

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis.

2022-10-123 citations

Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.

2021-08-011 citations

Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.

2021-07-014 citations

Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis.

2021-06-163 citations

Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report

Journal of Drugs in Dermatology2020-09-014 citations